Skip to main navigation

Live - Top Menu

  • Clinical Trials
  • Investors & Media
  • Careers
  • Contact Us
Menu
Close

Main navigation

  • Our Focus
  • Our Research
  • Our Medicine
  • Our Story
Home > Investors & Media > Press Releases
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
    • Financial Information
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Contact Us

Shareholder Tools

  • Email Alerts
  • Download Library
  • RSS
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter

Press Releases

Press Releases

Feb 25, 2020
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Issues 2020 Operating Expense Guidance and Provides Business Update
Worldwide Ocaliva net sales of $249.6 million for the full year 2019, representing 40% growth over the prior year Our NDA was the first accepted by the FDA for liver fibrosis due to NASH Completed enrollment of REVERSE, our Phase 3 study evaluating OCA for the treatment of compensated cirrhosis due
Read More
Feb 18, 2020
Intercept to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
NEW YORK , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2019 financial
Read More
Jan 29, 2020
Intercept Completes Enrollment of Phase 3 REVERSE Study Evaluating Obeticholic Acid for the Treatment of Compensated Cirrhosis due to NASH
NEW YORK , Jan. 29, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has completed patient enrollment in
Read More
Jan 08, 2020
Intercept to Present at the 38th Annual J.P. Morgan Healthcare Conference
NEW YORK , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski , M.D., President and
Read More
Dec 13, 2019
Intercept Provides Regulatory Update
Company submits Marketing Authorization Application to the European Medicines Agency for obeticholic acid in patients with fibrosis due to NASH FDA notifies Intercept of tentative date for previously announced Advisory Committee meeting NEW YORK , Dec.
Read More
Dec 10, 2019
Intercept to Host NASH Commercial Day for Investors on December 16, 2019 in New York
NEW YORK , Dec. 10, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will host a NASH Commercial Day for
Read More
Dec 05, 2019
Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet
NEW YORK , Dec. 05, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the positive results from the interim
Read More
Dec 02, 2019
Intercept Pharmaceuticals Appoints Jason Campagna as Chief Medical Officer
NEW YORK , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Jason Campagna , M.D.,
Read More
Nov 25, 2019
FDA Accepts Intercept’s NDA for OCA for the Treatment of Liver Fibrosis Due to NASH and Grants Priority Review
NDA supported by positive interim analysis results from the Phase 3 REGENERATE study demonstrating OCA’s improvement of liver fibrosis without worsening of NASH NEW YORK , Nov. 25, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the
Read More
Nov 08, 2019
New REGENERATE Interim Analysis Data Presented at The Liver Meeting® Report OCA Improved Multiple Noninvasive Markers of Liver Fibrosis in Patients with NASH
Treatment with OCA resulted in early and sustained improvements of commercially available noninvasive biomarker and imaging assessments of fibrosis Additional patient-reported outcomes data demonstrate that pruritus in patients treated with OCA 25 mg did not have an impact on measures of quality of
Read More

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
    • Financial Information
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Contact Us

Shareholder Tools

  • Email Alerts
  • Download Library
  • RSS
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter

Live - Footer Menu

  • Privacy Policy
  • Privacy Shield Policy
  • Corporate Compliance
  • Terms of Use
  • Contact Us
  • Cookie Preferences
10 Hudson Yards, 37th Floor|New York, NY 10001|T: 844-782-ICPT
© 2020 Intercept Pharmaceuticals, Inc.